News

March 2, 2020March 2, 2020

Statins, Metformin May Extend Survival in High-risk Prostate Cancer, Large Study Suggests

News

The use of statins — cholesterol-lowering agents to treat cardiovascular disease — alone or in combination with the diabetes treatment metformin, may increase survival in men with high-risk prostate cancer, ... Read more

February 27, 2020February 27, 2020

Decipher GRID ‘Signature’ Predicts Chemo Benefits in HSPC, Research Shows

News

Decipher Bioscience’s proprietary artificial intelligence platform, Decipher GRID, one of the world’s largest urologic cancer genomic databases, can be used to identify subtypes of prostate cancer and predict which men ... Read more

February 26, 2020February 26, 2020

High Vegetable Diet Does Not Halt Prostate Cancer, Study Finds

News

Contrary to popular opinion, eating a diet high in vegetables does not reduce the risk of prostate cancer progression in men with early-stage disease, findings from a Phase 3 trial ... Read more

February 24, 2020February 24, 2020

Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows

News

The combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) is safe and shows clinically meaningful activity, leading to lasting responses in men with metastatic castration-resistant prostate cancer (mCRPC), a Phase 1b trial ... Read more

February 20, 2020February 20, 2020

Adding Provenge to Xtandi, Zytiga Reduces Risk of Death by 45% in mCRPC Patients, Data Shows

News

Adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) or Xtandi (enzalutamide) significantly extends the lives of men with metastatic castration-resistant prostate cancer (mCRPC) in ... Read more

February 19, 2020February 19, 2020

Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show

News

Trovagene’s investigational oral therapy onvansertib helps overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), latest data from a Phase 2 clinical trial show. These results also highlighted ... Read more

February 17, 2020February 17, 2020

eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest

News

Daily treatment with a low dose of eRapa, Emtora Biosciences‘ new formulation of the therapeutic agent rapamycin, was safe and well tolerated, and led to immune system cell boosting in ... Read more

February 12, 2020February 12, 2020

UPenn Researchers Awarded $500K Grant to Develop CAR T-cell Therapy for Advanced PC

News

A research team at the Abramson Cancer Center of the University of Pennsylvania has been awarded a $500,000 grant from the Alliance for Cancer Gene Therapy (ACGT) to develop a ... Read more

February 11, 2020February 13, 2020

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

News

Treatment with Xtandi (enzalutamide) significantly extends the lives of men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), according to final data from a Phase 3 clinical trial. Developed by Pfizer and Astellas Pharma, Xtandi ... Read more

February 10, 2020February 10, 2020

Concerto, Pfizer Expand Data Partnership to Include Prostate, Other Cancers

News

Concerto HealthAI and Pfizer Oncology are expanding a collaboration using real-world data (RWD) to advance study design to include a range of cancers, including prostate cancer. The expansion builds on ... Read more